ABSTRACT
African-American than in Caucasian subjects. 5. Fracture thresholds based on BMD have been proposed but have yet to be adequately verified. BMD
does not necessarily correlate with risk of fracture as shown for fluoride-treated patients. 6. The WHO criteria (Kanis, 1994) for the diagnosis of osteoporosis and osteopenia are based on
standard deviations from the mean T-score of a single population and remain controversial. 7. A marked increase in BMD suggests bone dysplasia or myelophthistic disease. 8. An increase in spinal BMD coupled with a decrease in vertebral height is usually consistent with
partial collapse of a vertebra. 9. Patients with an increase in BMD in response to bisphosphonate treatment have a lower fracture risk
than patients with a decrease in BMD; however, greater increases in BMD do not reliably predict greater decreases in fracture risk.
